{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:44:49Z","timestamp":1788918289663,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.14283\/jpad.2024.126","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T09:17:42Z","timestamp":1719393462000},"page":"1228-1240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease"],"prefix":"10.1016","volume":"11","author":[{"given":"Tianle","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Hutchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rubel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Montenigro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"O'Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2024.126_bib1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.neuron.2013.12.003","article-title":"Biomarker modeling of Alzheimer's disease","volume":"80","author":"Jack","year":"2013","journal-title":"Neuron"},{"key":"10.14283\/jpad.2024.126_bib2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2024.126_bib3","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat Med"},{"key":"10.14283\/jpad.2024.126_bib4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.14283\/jpad.2024.126_bib5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer's disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat Aging"},{"key":"10.14283\/jpad.2024.126_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-030-05542-4_2","article-title":"The role of biomarkers in Alzheimer's disease drug development","volume":"1118","author":"Cummings","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.14283\/jpad.2024.126_bib7","author":"Papaliagkas"},{"key":"10.14283\/jpad.2024.126_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/01.wad.0000191420.61260.a8","article-title":"The role of biomarkers in clinical trials for Alzheimer disease","volume":"20","author":"Thal","year":"2006","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.14283\/jpad.2024.126_bib9","author":"Yiannopoulou"},{"key":"10.14283\/jpad.2024.126_bib10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s13311-022-01201-2","article-title":"Disease-modifying therapies for Alzheimer's disease: more questions than answers","volume":"19","author":"Golde","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.14283\/jpad.2024.126_bib11","doi-asserted-by":"crossref","first-page":"e12385","DOI":"10.1002\/trc2.12385","article-title":"Alzheimer's disease drug development pipeline: 2023","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.14283\/jpad.2024.126_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.14283\/jpad.2024.126_bib13","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.14283\/jpad.2024.126_bib14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2024.126_bib15","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-\u03b2 pathway in Alzheimer's disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.14283\/jpad.2024.126_bib16","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","article-title":"Developing the ATX(N) classification for use across the Alzheimer disease continuum","volume":"17","author":"Hampel","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.14283\/jpad.2024.126_bib17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"10.14283\/jpad.2024.126_bib18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.14283\/jpad.2024.126_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13195-023-01314-6","article-title":"Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants","volume":"15","author":"Dubois","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2024.126_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WAD.0000000000000144","article-title":"Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial","volume":"30","author":"Sevigny","year":"2016","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.14283\/jpad.2024.126_bib21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/alz.12748","article-title":"The AHEAD 3\u201345 study: design of a prevention trial for Alzheimer's disease","volume":"19","author":"Rafii","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2024.126_bib22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.14283\/jpad.2024.126_bib23","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0b013e3182840bbe","article-title":"Brain \u03b2-amyloid load approaches a plateau","volume":"80","author":"Jack","year":"2013","journal-title":"Neurology"},{"key":"10.14283\/jpad.2024.126_bib24","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(13)70090-5","article-title":"Tau pathology and neurodegeneration","volume":"12","author":"Spillantini","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.14283\/jpad.2024.126_bib25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12974-020-01820-6","article-title":"The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer's disease: a longitudinal PET study","volume":"17","author":"Ismail","year":"2020","journal-title":"J Neuroinflammation"},{"key":"10.14283\/jpad.2024.126_bib26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"key":"10.14283\/jpad.2024.126_bib27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/WCO.0000000000001035","article-title":"Overview of tau PET molecular imaging","volume":"35","author":"Cassinelli Petersen","year":"2022","journal-title":"Curr Opin Neurol"},{"key":"10.14283\/jpad.2024.126_bib28","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/brain\/aww023","article-title":"Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages","volume":"139","author":"Schwarz","year":"2016","journal-title":"Brain"},{"key":"10.14283\/jpad.2024.126_bib29","first-page":"748","article-title":"Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition","volume":"140","author":"Pontecorvo","year":"2017","journal-title":"Brain"},{"key":"10.14283\/jpad.2024.126_bib30","doi-asserted-by":"crossref","first-page":"e14022","DOI":"10.15252\/emmm.202114022","article-title":"Soluble p-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau","volume":"13","author":"Mattsson-Carlgren","year":"2021","journal-title":"EMBO Mol Med"},{"key":"10.14283\/jpad.2024.126_bib31","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease","volume":"143","author":"Mattsson-Carlgren","year":"2020","journal-title":"Brain"},{"key":"10.14283\/jpad.2024.126_bib32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","article-title":"Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.14283\/jpad.2024.126_bib33","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","article-title":"Tau kinetics in neurons and the human central nervous system","volume":"97","author":"Sato","year":"2018","journal-title":"Neuron"},{"key":"10.14283\/jpad.2024.126_bib34","doi-asserted-by":"crossref","first-page":"e14408","DOI":"10.15252\/emmm.202114408","article-title":"Blood-based biomarkers for Alzheimer's disease","volume":"14","author":"Leuzy","year":"2022","journal-title":"EMBO Mol Med"},{"key":"10.14283\/jpad.2024.126_bib35","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat Med"},{"key":"10.14283\/jpad.2024.126_bib36","author":"Yakoub"},{"key":"10.14283\/jpad.2024.126_bib40","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1212\/WNL.0000000000203868","article-title":"GRADUATE I and II: findings of two phase III randomized placebo-controlled studies assessing the efficacy and safety of subcutaneous gantenerumab in early Alzheimer's disease (AD)","volume":"100","author":"Smith","year":"2023","journal-title":"Neurology"},{"key":"10.14283\/jpad.2024.126_bib41","author":"Safety and efficacy study of gantenerumab in participants with early Alzheimer's disease (AD)"},{"key":"10.14283\/jpad.2024.126_bib44","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.14283\/jpad.2024.126_bib45","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2024.126_bib47","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.14283\/jpad.2024.126_bib50","doi-asserted-by":"crossref","first-page":"e12434","DOI":"10.1002\/dad2.12434","article-title":"Operationalizing the centiloid scale for 18Fflorbetapir PET studies on PET\/MRI","volume":"15","author":"Coath","year":"2023","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.14283\/jpad.2024.126_bib51","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2967\/jnumed.122.263926","article-title":"Longitudinal tau PET using 18F-flortaucipir: the effect of relative cerebral blood flow on quantitative and semiquantitative parameters","volume":"64","author":"Visser","year":"2023","journal-title":"J Nucl Med"},{"key":"10.14283\/jpad.2024.126_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2024.126_bib53","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2967\/jnumed.121.263694","article-title":"Tau beats amyloid in predicting brain atrophy in Alzheimer disease: implications for prognosis and clinical trials","volume":"63","author":"Malpetti","year":"2022","journal-title":"J Nucl Med"},{"key":"10.14283\/jpad.2024.126_bib54","doi-asserted-by":"crossref","first-page":"e12454","DOI":"10.1002\/dad2.12454","article-title":"CenTauR: toward a universal scale and masks for standardizing tau imaging studies","volume":"15","author":"Villemagne","year":"2023","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.14283\/jpad.2024.126_bib55","doi-asserted-by":"crossref","first-page":"e082006","DOI":"10.1002\/alz.082006","article-title":"Harmonization of tau-PET in Alzheimer's disease: comparison of methods to derive CenTauR units for [18F]RO948, [18F]flortaucipir, and [18F]MK-6240","volume":"19","author":"Leuzy","year":"2023","journal-title":"Alzheimer Dement"},{"key":"10.14283\/jpad.2024.126_bib56","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1541-0420.2011.01682.x","article-title":"Evaluating correlation-based metric for surrogate marker qualification within a causal correlation framework","volume":"68","author":"Wang","year":"2012","journal-title":"Biometrics"},{"issue":"4S_part_7","key":"10.14283\/jpad.2024.126_bib57","first-page":"P289","article-title":"Correlation of brain atrophy with clinical progression in mild-to-moderate Alzheimer's disease: results from the volumetric MRI substudies of two phase III trials with bapineuzumab","volume":"9","author":"Novak","year":"2013","journal-title":"Alzheimer's Dement"},{"key":"10.14283\/jpad.2024.126_bib58","series-title":"Alzheimer's Disease Drug Development: Research and Development Ecosystem","year":"2022"},{"key":"10.14283\/jpad.2024.126_bib60","series-title":"The Evaluation of Surrogate Endpoints","year":"2006"},{"key":"10.14283\/jpad.2024.126_bib61","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/cpt.2536","article-title":"Toward bridging unmet medical need in early Alzheimer's disease: an evaluation of beta-amyloid (A\u03b2) plaque burden as a potential drug development tool","volume":"111","author":"Zhu","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.14283\/jpad.2024.126_bib62","unstructured":"Scelsi M, Jackson J, Tonietto M, et al. An exploration of amyloid removal measures in relation to clinical benefit: a review and metaregression of anti-amyloid trials in AD. Presented at: CTAD23; October 24\u201327, 2023; Boston, MA."},{"key":"10.14283\/jpad.2024.126_bib63","author":"Tau-PET Harmonization Working Group"},{"key":"10.14283\/jpad.2024.126_bib64","author":"Head-to-head harmonization of tau tracers in Alzheimer's disease (HEAD)"},{"key":"10.14283\/jpad.2024.126_bib65","author":"Global Biomarker Standardization Consortium (GBSC)"},{"key":"10.14283\/jpad.2024.126_bib66","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13195-020-00738-8","article-title":"Amyloid-\u03b2 misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline","volume":"12","author":"Stockmann","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2024.126_bib67","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of solanezumab in preclinical Alzheimer's disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N Engl J Med"},{"key":"10.14283\/jpad.2024.126_bib69","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1038\/s41467-023-42596-6","article-title":"Plasma biomarkers predict Alzheimer's disease before clinical onset in Chinese cohorts","volume":"14","author":"Cai","year":"2023","journal-title":"Nat Commun"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724006526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724006526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:14:41Z","timestamp":1737339281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724006526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2274580724006526"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2024.126","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2024.126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}